Vaxart Q4 2023 GAAP EPS $(0.12) Beats $(0.14) Estimate, Sales $3.245M Beat $1.250M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vaxart (NASDAQ:VXRT) reported Q4 2023 earnings with a smaller loss per share of $(0.12) compared to the expected $(0.14), and a significant sales increase to $3.245M, surpassing the $1.250M estimate. This marks a substantial improvement over the previous year's performance.
March 14, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxart reported a smaller Q4 2023 loss of $(0.12) per share, beating estimates, and sales of $3.245M, significantly above expectations.
Vaxart's Q4 2023 performance exceeded analyst expectations in both EPS and sales, indicating a strong financial improvement and potential growth trajectory. The significant beat on both fronts, especially the sales figure which was more than double the estimate, suggests a positive outlook for the company's stock in the short term. The comparison to last year's figures highlights the company's progress and may increase investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100